| Title : A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease - Farlow_2000_Eur.Neurol_44_236 |
| Author(s) : Farlow M , Anand R , Messina J, Jr. , Hartman R , Veach J |
| Ref : Eur Neurol , 44 :236 , 2000 |
|
Abstract :
The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon, in patients with mild to moderately severe Alzheimer's disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. By 52 weeks, patients originally treated with 6-12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo. |
| PubMedSearch : Farlow_2000_Eur.Neurol_44_236 |
| PubMedID: 11096224 |
Farlow M, Anand R, Messina J, Jr., Hartman R, Veach J (2000)
A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease
Eur Neurol
44 :236
Farlow M, Anand R, Messina J, Jr., Hartman R, Veach J (2000)
Eur Neurol
44 :236